Often patients with hepatitis B ask their doctors, “I’m taking nucleoside antivirals, when can I stop taking them? Some patients say I’ve been taking them for 2 years, can I stop? Or that the course of treatment set by the doctor is 2 years. In fact, these are not accurate, there is no fixed course of nucleoside drugs, hepatitis B antiviral treatment advocates individualized, each patient’s discontinuation time depends on the specific situation, some patients need long-term medication. It is important to note that during antiviral treatment, HBV-DNA, liver function, and hepatitis B half tests must be reviewed every few months to assess the effectiveness of treatment. The guidelines of the European Society of Hepatology, the American College of Hepatology, the Asia Pacific Society of Hepatology, and the Liver Institute of mainland China for the prevention and treatment of hepatitis B are different for different conditions. For patients with hepatitis B cirrhosis, the universities will be more consistent because the disease has caused more serious organic lesions in the liver, and oral nucleoside antiviral drugs are required for long-term use, that is, they cannot be discontinued. Because after stopping the drug if the virus replicates again, the disease rebound, the consequences are very serious, and even cause liver failure. With antiviral therapy for cirrhotic patients, the inflammatory lesions and fibrosis of the liver can be partially reversed, and decompensated cirrhosis can become stable, reducing ascites and bleeding. For patients who were “major triple-positive” before treatment, after HBV-DNA turns negative and e antigen serologically converts (i.e. major triple-positive becomes minor triple-positive), at least one more year of medication and more than 3 years of total treatment can be considered to stop the medication for observation. For patients with “minor triplet” before treatment, long-term medication is advocated, or discontinue medication after HBV-DNA turns negative, hepatitis B surface antigen turns negative, and surface antibodies appear, but this is difficult to achieve, so long-term medication is basically required. Even after discontinuing the medication for patients with major triplet to minor triplet, there is still a risk of relapse because nucleoside analogs can only inhibit viral replication and are for relaxed HBV-DNA inhibition, while they cannot kill superhelix HBV-DNA. The rebound after stopping the medication depends on the immune status of the body, once the immunity is reduced, the virus can replicate up again. In general, oral nucleoside analogs tend to be long-term treatments, and although liver disease guidelines do not recommend long-term treatment for all hepatitis B patients, the longer the antiviral effect can last, the better, judging from the long-term antiviral effects observed in clinical practice and the changes in the patient’s condition after discontinuation of the drug.